BioSpace News Archive

Artelo Biosciences, Inc. today announced that Professor Saoirse O’Sullivan, Artelo’s Vice President of Translational Sciences, will be presenting at the 13th Congress of the European Pain Federation (EFIC) being held September 20-22, 2023.

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”) is pleased to announce that the Company has completed a Pre-Investigational New Drug (“Pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first ExoTherapy product, after receiving a written response from the FDA on August 29, 2023.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced its participation in the Cantor Fitzgerald Global Healthcare Conference 2023, which will be held on September 26-28, 2023 at the InterContinental Barclay Hotel in New York City.

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer and the Note.

Wellysis, a spin-off company from Samsung SDS, has received clearance from the U.S. Food and Drug Administration (FDA) on August 30, 2023, to market its wearable electrocardiography (ECG) patch, S-Patch Ex, in the U.S.Wellysis, a spin-off company from Samsung SDS, has received clearance from the U.S. Food and Drug Administration (FDA) on August 30, 2023, to market its wearable electrocardiography (ECG) patch, S-Patch Ex, in the U.S.

ArisGlobal, a market-leader in global drug development technology solutions, announced today that medac, a German-based pharmaceutical manufacturer specializing in the fields of oncology and hematology, urology, and autoimmune diseases, has chosen LifeSphere Safety to modernize its drug safety processes.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced its commitment to improving outcomes for patients with prostate cancer through its participation in the Hampton University Proton Therapy Institute Prostate Cancer & Men’s Health Fair.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for resmetirom for the treatment of adult patients with NASH with liver fibrosis.

Us2.ai, a Singapore-based MedTech firm, has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, to enable earlier detection, improved diagnosis and more efficient management of heart disease.

Uvax Bio LLC announced today that Pedro Garbes, MD., has joined the company as Vice President, Global Medical Lead.